Federal Register / Vol. 71, No.
162 / Tuesday, August 22, 2006 / Notices
Drug
Gamma hydroxybutyric acid
(2010).
Ibogaine (7260) .............................
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) ......
Dimethyltryptamine (7435) ............
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) .............
Amobarbital (2125) .......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ...................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine(9120) ...................
Oxycodone (9143) ........................
Hydromorphone (9150) .................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) .........................
Metazocine (9240) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ....................
Fentanyl (9801) .............................
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than October 23, 2006.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13840 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
cprice-sewell on PROD1PC66 with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
VerDate Aug<31>2005 15:34 Aug 21, 2006 Jkt 208001
48945
Schedule substance in Schedule I or II and prior
to issuing a registration under 21 U.S.C.
I 952(a)(2) authorizing the importation of
such a substance, provide
I Dated: August 15, 2006.
manufacturers holding registrations for
I the bulk manufacture of the substance
I Deputy Assistant Administrator, Office of
I an opportunity for a hearing.
I Therefore, in accordance with 21 CFR
II 1301.34(a), this is notice that on March
II 31, 2006, Applied Science Labs,
II Division of Alltech Associates Inc., 2701
II Carolean Industrial Drive, State College,
II Pennsylvania 16801, made application
II
by renewal to the Drug Enforcement
II
Administration (DEA) to be registered as
II
II an importer of the basic classes of
II controlled substances listed in Schedule
II I and II:
II
II Drug
II
II Heroin (9200) ................................
II Cocaine (9041) .............................
II Codeine (9050) .............................
II Meperidine (9230) .........................
Methadone (9250) ........................
Morphine (9300) ...........................
The company plans to import these
controlled substances for the
manufacture of reference standards.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 21, 2006.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
PO 00000 Frm 00039 Fmt 4703 Sfmt 4703
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Joseph T. Rannazzisi,
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13843 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Schedule Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
I this is notice that on June 6, 2006,
II Cambrex North Brunswick, Inc.,
II Technology Centre of New Jersey, 661
II
II Highway One, North Brunswick, NJ
II 08902, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in Schedule
I and II:
Drug Schedule
N-Ethylamphetamine (1475) ......... I
Tetrahydrocannabinols (7370) ...... I
2,5–Dimethoxyamphetamine I
(7396).
3,4–Methylenedioxyamphetamine I
(7400).
4–Methoxyamphetamine (7411) ... I
Amphetamine (1100) .................... II
Methamphetamine (1105) ............. II
Methylphenidate (1724) ................ II
Pentobarbital (2270) ..................... II
Phenylacetone (8501) ................... II
Hydromorphone (9150) ................. II
Hydrocodone (9193) ..................... II
Methadone (9250) ........................ II
Methadone Intermediate (9254) ... II
Morphine (9300) ........................... II
Sufentanil (9740) .......................... II
Fentanyl (9801) ............................. II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ ODL;
E:\FR\FM\22AUN1.SGM 22AUN1